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Prohormone convertase 1/3 (PC1/3), encoded by the PCSK1 gene, is a serine endoprotease which is involved in
the processing of a variety of proneuropeptides andprohormones. Humanswhoare homozygous or compound
heterozygous for loss-of-functionmutations in PCSK1 exhibit a variable and pleiotropic syndrome consisting of
someorallof the following:obesity,malabsorptivediarrhea,hypogonadotropichypogonadism,altered thyroid
and adrenal function and impaired regulation of plasma glucose levels in association with elevated circulating
proinsulin-to-insulin ratio. Recently,more commonvariants in thePCSK1genehavebeen found tobeassociated
with alterations in body mass index, increased circulating proinsulin levels and defects in glucose homeostasis.
This review provides an overview of the endocrinopathies and other disorders observed in PC1/3-deficient
patients, discusses the possible biochemical basis for these manifestations of the disease and proposes a model
whereby certain missense mutations in PCSK1 may result in proteins with a dominant negative action.
A. Proprotein convertases regulate protein function
I. Introduction
THE PROPROTEIN CONVERTASES (PCs) are calci-um-dependent serine endoproteases involved in the
processing of a variety of cellular precursors in the secre-
tory pathway. Because of the homology of their catalytic
domains to that of bacterial subtilisin and yeast kexin, the
corresponding genes are known as subtilisin and kexin-
like proprotein convertases (PCSKs). In mammals the PC
family contains seven closely related members: PC1/3
(PCSK1), PC2 (PCSK2), furin (PCSK3), PC4 (PCSK4),
PC5/6 (PCSK5), PACE4 (PCSK6), and PC7 (PCSK7); and
two less related enzymes SKI-1 (PCSK8) and PCSK9
(PCSK9) (1, 2). The seven closely related enzymes, here
referred as the PC family, catalyze proteolytic cleavage
C-terminally to basic residuemotifs. PCs are composed of
three common domain structures, a prodomain, a cata-
lytic domain andaPdomain (also calledhomoBormiddle
domain), and a unique C-terminal region, which can be
composed of several subdomains. The common domains
are essential and sufficient for catalytic activity, while the
C-terminal regions are important for intracellular traf-
ficking and subcellular localization. Because of the high
homology in the catalytic (50%–60%) and P (30%-
40%) domains, substrate specificity is largely overlap-
ping, albeit by no means identical. The enzymes differ in
tissue distribution, subcellular localization and pH op-
tima, which largely determines substrate selectivity in
vivo. For instance, furin, PACE4, PC5/6, and PC7 are
widely expressed enzymes that process a large number of
substrates (eg, growth factors, plasma proteins, viral coat
proteins, and bacterial toxins) and exert their action at
different compartments along the constitutive secretory
and endocytic pathways (1). In contrast, PC1/3 and PC2,
are only expressed in neural and endocrine tissues, where
they cleave prohormones and proneuropeptides within
the secretory granules of the regulated secretory pathway
(3).
B. The neuroendocrine member PC1/3: General
properties
Prohormone convertase 1/3 (PC1/3; also known as
PC1, PC3 and SPC3) was cloned in 1991 by two labora-
tories independently (4, 5). ThePCSK1 gene consists of 14
exons located on chromosome 5 in humans and 13 inmice
(6). Northern blot analysis of human tissues and cells re-
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vealed the presence of a dominant transcript of 6.2 kb, the
major sites of expressionbeing thepituitary, thebrain, and
the endocrinepancreas (7).ThePCSK1promoter contains
CRE-1 and CRE-2 transcriptional elements which can be
transactivated byCREB-1 andATF1 transcription factors
(8, 9). The PCSK1 gene encodes the 753-amino acid pre-
cursor preproPC1/3, from which the signal peptide is re-
moved cotranslationally in the endoplasmic reticulum
(ER). The resulting product is a proPC1/3 zymogen of 94
kDa which is unable to cleave substrates in trans but able
to cleave its prodomain (also known as prosegment or
propeptide) in cis. The structural domains of PC1/3 are
depicted schematically in Figure 1A. The prodomain is
involved in proper folding and early enzyme inhibition.
The catalytic domain includes the catalytic triad Asp167-
His208-Ser382, which is conserved between bacterial sub-
tilisin, yeast kexin, and all mammalian PCs, and the oxy-
anion hole Asn309, which is conserved in all PCs except
PC2. The P domain contributes to calcium and pH re-
quirements and to enzyme stability (10). The C-terminal
(Ct) domainofPC1/3 is involved in sorting to the secretory
granules and in enzyme stability.
Like the other eukaryotic proprotein convertases,
PC1/3 recognizes and cleaves precursor proteins C-termi-
nally to a pair of basic residues. PC1/3 prefers to cleave
after a Lys-Arg dibasic site, but it is also able to cleave
other dibasic sites including Arg-Arg, Arg-Lys, Arg-X-X-
Arg (whereX is any amino acid), or even after a single Arg
residue (11). Substrates containing large residues (Trp,
Tyr) or Pro in the P1 and P2 sites are preferentially
cleaved by PC2 and not by PC1/3 (11). PC1/3 enzymatic
activitydependson thepresenceofmMofcalcium invitro,
although this calcium requirement is different for full
length and C-terminally cleaved PC1/3 (as discussed be-
low) (12, 13). In terms of substrate specificity, expression
and localization, PC1/3mostly resembles PC2. Regarding
substrate specificity, it has recently been shown that the
single substitution of Ser357, located in the catalytic do-
main, by Gly in PC1/3 (a variant found in PC1/3 cloned
from human lung tumor cells (14)) results in a hypermor-
phic PC1/3 form with PC2-like activity (15). In addition,
both PC1/3 and PC2 bind to specific neuroendocrine
chaperones (proSAAS in the case of PC1/3; 7B2 in the case
of PC2). Despite these similarities, there are clear differ-
ences between both convertases. For example, while PC2
absolutely requires the presence of 7B2 for activation (16,
17), PC1/3 can be activated independently of the binding
of proSAAS. ProSAAS, a granin-like protein discovered
using proteomic studies on the brain of mice lacking car-
boxypeptidase E (18), is able to potently inhibit PC1/3
activity (18–20), suggesting that proSAAS is an endoge-
nous inhibitor of PC1/3 and that the binding proSAAS-
PC1/3 blocks the PC1/3 enzymatic activity at early stages
of the regulated secretory pathway. Another difference is
that PC2 has amuch larger range of substrates then PC1/3
(3).
PC1/3 is predominantly expressed in neural and endo-
crine tissues. In the brain, PC1/3 expression is especially
high in the hypothalamus (21), but it is also present in
other areas such as cerebral cortex, hippocampus, and
cerebellum (22–24). In peripheral tissues, PC1/3 is mainly
located in adrenal medulla, pituitary, thyroid gland, en-
docrine pancreas (especially in-cells), and small intestine
(eg, enteroendocrine L and K cells) (25–31). PC1/3 ex-
pression can also be detected, albeit at very low levels, in
adipocytes (32), in the proglucagon-producing -cells of
the pancreatic islets (30), in lung tumors (14, 33), and in
certain types of immune cells (34, 35).
PC1/3 is crucial for the processing of a number of neu-
ropeptides and peptide hormones such as proopiomela-
nocortin (POMC), proinsulin and proglucagon. Impor-
tantly, in some cases PC1/3 activity is sufficient to produce
the endproduct from theprecursor.This is for instance the
case in the synthesis of adrenocorticotropic hormone
(ACTH) from POMC in the anterior lobe of the pituitary
gland (36, 37) and the glucagon-like peptides GLP-1,
GLP-2, oxyntomodulin andglicentin fromproglucagon in
the small intestine (38, 39). In other cases, the generation
of a given hormone or neuropeptide requires the addi-
tional action of PC2. For example, both PC1/3 and PC2
are coexpressed in the intermediate lobe of the pituitary
and the hypothalamic POMCneurons,where they accom-
plish the proteolytic cleavage of POMC to -melanocyte-
stimulating hormone (-MSH) (37, 40), and the islets of
Langerhans in the pancreas, where both enzymes are re-
quired for the synthesis of insulin from proinsulin (41–
44). In addition to PCs, the synthesis of -MSH requires
the complementary action of other enzymes including
acetylases, amidases and carboxypeptidases (45).
C. Structural aspects of PC1/3
Prodomain
In PCs, the prodomain is thought to assist the correct
folding and to regulate the pH-dependent activation of the
catalytic domain (46, 47). In PC1/3 the prodomain is
formed by 83 residues and is highly conserved between
orthologues (80%of sequence identity), although is not
well conserved amongparalogues of the convertase family
(30%-40%). Like other members of the PC family, ex-
cept PC2 (48) and PC7 (49), proPC1/3 accomplishes au-
toproteolytic cleavage of the prodomain at the primary
site RSKR110 before exiting the ER (50). At this stage, the
protein is referred as PC1/3, although the propeptide is
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Figure 1.
PC1/3 maturation in the regulated secretory pathway. A. The catalytic domain (CAT) contains the catalytic triad, formed by Asp167-
His208-Ser382, and the oxyanion hole Asn309. The location of prodomain (PRO) and C-terminal (Ct) cleavage sites are indicated in dark blue and
red, respectively. Glycosylation is also required for proper PC1/3 activation. In mouse PC1/3 three glycosylation sites (N1, N2 and N3) are present of
which only N1 and N3 are used. In human PC1/3 only N1 and N2 sites are present of which only N1 is used (73). The RRGD motif (gray) present in
the P domain is critical for proper proPC1/3 processing and further sorting to the secretory granules. B. Stereo representation of the catalytic and P
domain of PC1/3, based on the crystal structure of furin (courtesy of Dr Manuel Than, Leibniz Institute for Age Research, Germany). It shows the
protein backbone in cartoon representation, the dec-RVKR-CMK inhibitor in dark blue marking in the active site cleft, and the two calcium ions in
purple. Also indicated are the catalytic residues Asp167, His208 and Ser382, and the oxyanion hole Asn309. The Asn222 residue, found
substituted by Asp in an obese mouse model (204), is indicated in green. The figure was created using PYMOL (DeLano Scientific LLC,
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still noncovalently attached. After ER exit, the compart-
ments of the secretory pathway become progressively
more acidic,which leads to partial unfolding of the prodo-
main and cleavage at the secondary site RRSRR81.
Whereas the first cleavage occurs rapidly (t1/2  2 min-
utes), the second cleavage and dissociation of the prodo-
main occurs more slowly, as is also the case for furin (51,
52). In vitro experiments showed that these steps require
apH lower than6.4 indicating thatdissociation could take
place in the trans-golgi network (TGN) (53).However, the
exact localization where dissociation of the prodomain
takes place has not been demonstrated yet. Several groups
have reported that the prosegments are able to inhibit PC
enzymatic activity (54–57), suggesting that this domain
might prevent PC1/3 enzymatic activity in early secretory
compartments. On the other hand, without a propeptide,
no active enzyme is formed and the misfolded protein is
retained in the ER. For furin it has been shown that ex-
pression of the propeptide in trans can rescue propeptide-
less furin, assist folding and facilitate ER exit (58). These
studies demonstrate the chaperoning function of the
propeptide.
The solution structure of mouse PC1/3 prodomain has
been determined using heteronuclear NMR spectroscopy
(59). The overall fold of the PC1/3 prodomain consists of
two -helices and four -strands forming an antiparallel
-sheet in a ––––– arrangement. It has been pro-
posed that a hydrophobic patch present in the solvent-
accessible surface of the -sheet might be buried at the
binding interfacewith the catalytic domain (59).No struc-
tural data about the prodomain of other members of the
eukaryotic PC family have been reported to date, although
it is generally assumed that other familymembers can also
exhibit the same overall fold because of the homology
among PC propeptides.
Catalytic domain
PCs contain the classical catalytic triad Asp-His-Ser in
the catalytic domain at topologically conserved positions
with bacterial subtilisins and yeast kexin. This domain
also includes the oxyanion hole Asnwhich is necessary for
stabilization of the tetrahedral intermediate during sub-
strate cleavage. The catalytic domain of human PC1/3 is
343 residues and the boundaries are based on homology
with bacterial subtilisins. The catalytic domain is themost
conserved region among PCs, with 50%–60% sequence
similarity. In comparison to the bacterial subtilisins, PCs
contains a large number of negatively charged residues in
their catalytic domain, which has been shown to confer
selectivity for basic substrate segments (60, 61).
The overall three-dimensional structure of mouse furin
comprising the catalytic and the P domains was deter-
mined by X-ray crystallography more than a decade ago
(62). This structure served as a template tomodel the other
members of the PC family by homologymodeling, includ-
ingPC1/3 (Figure 1B) (63).More recently, theX-ray struc-
ture of human furin in complex with some noncovalent
inhibitors has been reported (64). The core of the catalytic
domain of mouse and human furin consists of a highly
twisted -sheet composed of seven parallel and one an-
tiparallel -strand, which is flanked by five adjacent and
two peripheral helices and by two -hairpin loops. Be-
cause of the high sequence similarity among PCs, this
structural topology is likely conserved in all family mem-
bers, as suggested by the homology modeling analyses
(63). The polypeptide chain of the catalytic domain of
furin is cross-connected by twodisulfide bridges and it has
two calcium binding sites. The cysteine residues involved
in the formation of these disulfide bridges and the residues
involved in the calcium binding are conserved in PC1/3,
suggesting that PC1/3hasboth structural elements aswell.
P domain
The P domain is a well conserved region in PCs of ap-
proximately 150 residues and located C-terminal to the
catalytic domain. It is unique for PCs and absent in sub-
tilisins. In contrast to the spherical shape of the catalytic
domain, the P-domain topology is barrel-like. According
to theX-ray structure of furin and homologymodels of all
other PCs, the P-domain is organized as an eight-stranded
-barrel, in which the eight -strands are arranged in two
opposing four-stranded-sheets (Figure 1B) (62, 63). The
C-terminal boundary of the P domain is formed by the
conserved residuesGly593 andThr594whichare important
for the stabilization of the catalytic domain (65). The P-
domain is involved in the regulation of calcium and pH
dependent activation of PC1/3 (10). Furthermore the con-
served sequence Arg526-Arg-Gly-Asp529, also known as
RRGD motif (Figure 1A), is crucial for proper proPC1/3
Legend to Figure 1 Continued. . .
www.pymol.org). C. In the ER, PC1/3 is synthetized as preproPC1/3. After cotranslational signal peptide (S) removal, proPC1/3 (94 kDa) undergoes
protein folding, N-glycosylation and prodomain cleavage. In the early compartments of the Golgi apparatus, proPC1/3 sugar residues are modified
and finally PC1/3 is sulfated in the TGN. In the mildly acidic environment of the TGN, the prodomain is removed after an additional internal
cleavage, resulting in an active 87-kDa PC1/3 form. In the secretory granules (SG) 87-kDa PC1/3 is intermolecularly cleaved in the C-terminal tail at
two different cleavage sites, which results in the formation of the C-terminally truncated fully activated forms of 74 and 66-kDa.
4 PCSK1 mutations and human endocrinopathies Endocrine Reviews
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 18 May 2016. at 00:24 For personal use only. No other uses without permission. . All rights reserved.
processing and further sorting to the secretory granules
(66, 67).
Carboxyl terminal domain
TheC-terminal domains are unique for eachmemberof
the PC family, varying both in sequence and length. The
C-terminus of PC1/3 ismuch longer than that of PC2 (159
aa for PC1/3 and 44 aa for PC2) and is involved in the
sorting of this convertase to the dense core secretory gran-
ules, as well as in its enzyme activity and stability (50,
66–68). The granule-sorting signal resides in an amphi-
pathic -helix present in the C-terminal 43 amino acids
(68–70). Once PC1/3 is located in the secretory granules,
the C-terminus can be cleaved at two dibasic sites as dis-
cussed in more detail in the next section.
D. Cell biology of PC1/3: Maturation and trafficking
After signal peptide removal, the resulting zymogen,
proPC1/3 (94 kDa), requires N-glycosylation for proper
folding and prodomain cleavage (71) (Figure 1C). Mouse
PC1/3 contains three potential N-glycosylation sites of
which only Asn173 and Asn645 are glycosylated (72). Gly-
cosylation at Asn173 is necessary for autocatalytic activity
and ER exit, while glycosylation at Asn645 is not. Human
PC1/3 is only glycosylated at Asn173 (73). PC1/3 under-
goes several additional posttranslational modifications in
the Golgi, such as complex glycosylation and sulfation
(71, 74). In the TGN, 87-kDa PC1/3 form is packaged,
together with a number of prohormones and cargo pro-
teins, into immature secretory granules. In the acidic en-
vironment of the secretory granules, 87-kDa PC1/3 is fur-
ther intermolecularly cleaved at the C-terminal region,
which results in the formation two truncated forms: 74-
kDa and 66-kDa PC1/3 (Figure 1C). In contrast to the
87-kDa species, which possesses a relative low enzymatic
activity compared to other convertases (12), and tends to
form dimers, oligomers and aggregates (75), these trun-
cated forms (especially 66-kDa PC1/3) are more active,
exhibit higher calcium dependence and narrower pH op-
timum (5.0–5.5), and are mostly present as monomers
(75–78). The 74/66-kDa forms, however, are much less
stable than the nontruncated 87-kDa species (76–78).
PC1/3 substrate processing is detectable starting at the
TGN, which is in line with the pH requirements for the
secondaryprodomain cleavage (ie, the initial processingof
POMC; (53, 79)).
E. PC1/3 substrate specificity
In the past two and a half decades a significant propor-
tion of research in the proprotein convertase field has been
focused on identifying physiological substrates for PC1/3.
In vitro and in cellulo (experiments performed in cell cul-
tures) strategies using overexpression of substrate and/or
enzyme have been useful, but are prone to false positive
results. In cellulo experiments using knockdown or
knockout of PC1/3 are the preferred method to identify a
genuine substrate. Serum samples of PC1/3 null patients
have been instrumental in the identification of some phys-
iological substrates, but with the development of knock-
outmousemodels for PC1/3 substrate processing has been
assessed in most relevant tissues, such as brain, pituitary
and islets of Langerhans (3). Redundancy with other PCs,
in particular PC2, exists for certain substrates, sometimes
in a cell type-specific manner. A striking example is the
processing of proneurotensin and neuromedin N which
were reduced in whole brain extracts from Pcsk2 knock-
out mice by 15% and 50%, respectively (80). The degree
ofprocessingwas, however, dependenton thebrain region
investigated. Immunohistochemistry studies suggested re-
gion-specific redundancy by PC1/3 (80). Comparison of
peptidomic analyses from brain from Pcsk1 and Pcsk2
knockout mice showed that PC2 has more unique sub-
strates than PC1/3 and confirmed that PC1/3 has a pref-
erence for cleavage after Lys-Arg, Arg-Arg, Arg-Lys or
Arg-X-X-Arg, whereas PC2 has a preference for cleavage
afterLys-ArgandArg-Arg (81).Otherpotential substrates
have been identified or proposed by a variety of strategies.
Supplemental Table 1 provides an overview of potential
substrates and rates the supplied evidence for each sub-
strate to be an actual substrate in vivo.
II. PCSK1 mutations in disease; a spectrum of
phenotypes
A. Clinical aspects of PCSK1 deficiency
In 1995, O’Rahilly et al described a patient who pre-
sented with severe reactive hypoglycemia, evidence of im-
paired adrenal and thyroid function, and a history of hy-
pogonadotropic hypogonadism and severe obesity with
onset in infancy. The patient was found to have biochem-
ical evidence of a generalized defect in prohormone con-
version with plasma levels of prohormone to mature hor-
mone ratios indicating impaired proinsulin and POMC
processing (82). Subsequently, compound heterozygous
mutations in PCSK1 were identified in this patient: a del-
eteriousmutation PCSK1-p.G593R and amutation in the
splice donor site c.6204ACcausing exon skipping that
leads to a frameshift and hence protein truncation (83)
(OMIM: 600 955). This patient represented one of the
first examples of a mutation in a single gene leading to
obesity in humans. The patient had highly elevated levels
of intact and 64–65 des-split proinsulin but very low lev-
els of insulin. Proinsulin has reduced affinity for its recep-
tor but an increased half-life (84), which is the likely ex-
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planation for the postprandial hypoglycemia observed in
this patient. Three additional patients have since been
identified by the same group, one of which was homozy-
gous and the other two combined heterozygous for dele-
terious mutations in PCSK1 (85–87). Since these patients
exhibited features of intestinal malabsorption, the early
clinical history of the first PC1/3 null patient was re-eval-
uated, revealing that in the first decade of life, despite
severe obesity, she also suffered from frequent diarrhea
and was investigated by intestinal biopsy because of clin-
ical suspicion of celiac disease. Throughout her life the
patient has suffered from intermittent constipation and
diarrhea.
In 2013, exome sequencing of 35 children with idio-
pathic malabsorptive diarrhea revealed 13 patients with
PC1/3deficiency (88). Todate twenty onePC1/3-deficient
patients carrying different PCSK1 mutations have been
identified, most of them located in the catalytic domain
and in the P domain (Supplemental Table 2). Several non-
sense mutations cause a premature stop codon leading to
truncated proteins. All mutations cause a complete loss of
activitymeasured in vitro, except for the PCSK1-p.P258T
mutation which retains approximately 50% of activity
compared to PCSK1-WT (88). However, the patient with
the PCSK1-p.P258T mutation was compound homozy-
gous for both the deleterious PCSK1-p.G209R mutation
and the PCSK1-p.P258T mutation. Coexpression of the
twomutant proteins in vitro showed that the catalytically
inactive PCSK1-p.G209R mutant retains the PCSK1-
p.P258T in theERand therefore renders it inactive against
substrates in trans (89). The expression of the different
symptoms of the syndrome varies between patients. Thus
far, 17 of 21 patients described are male suggesting the
possibility of selective earlymortality in females. The clin-
ical phenotypes and diagnostic tests are depicted in Table
1.
Early-onset obesity and hyperphagia
Most the patients (17/17; four not described) were re-
ported to suffer fromearly-onset obesity andhyperphagia.
However, patients suffered fromprofoundweight loss be-
fore intervention with parenteral feeding and failure to
thrive. Despite the fact that some patients displayed mor-
bid obesity and severe hyperphagia, other subjects were
onlymoderately obese (zBMI2.3). Somepatients needed
food restriction, in some cases even locking the pantry and
refrigerator (90). In general, body mass index (BMI)
started to rise from the age of 2, andpatients becameobese
from early childhood and continued to be so (88, 90, 91).
However, the extreme obesity of the index case at 3 years
of age (zBMI5.3; (82, 83)) has not been reported in any
subsequent patients. Interestingly, in many patients a
moderate increase in body weight coincided with short
stature, implicating that gains in BMI are not only due to
weight increases (88, 90). When tested in one patient, en-
ergy expenditure was in the normal range while the in-
crease in food intake during an ad libitum meal was ap-
proximately twofold, comparable with patients with
mutations in the melanocortin 4 receptor (MC4R) (86).
Malabsorption of fatty acids, amino acids and
monosaccharides
In 2003, Jackson et al reported for the first time that
deficiency of PC1/3 activity results in a severe neonatal
diarrhea and intestinal malabsorption (85). All subse-
quent PC1/3 null patients have been reported with small-
intestinal dysfunction (86, 88, 90–93). In general, the gas-
trointestinal (GI) complicationsbeginvery soonafterbirth
(the first week of life), most children requiring hospital-
ization and parenteral nutrition due to recurrent watery
diarrhea. As a consequence of the chronic diarrhea, the
patients suffer weight loss, dehydration andmetabolic ac-
idosis. Because of the severity of the symptoms, several
Table 1. Overview of clinical phenotype of PC1/3-deficient patients. Abbreviations in this table: ACTH:
adrenocorticotropic hormone; BMI: body mass index; FSH: follicle stimulating hormone; GLP-1: glucagon-like peptide
1; IGF-1: insulin growth factor 1; LH: luteinizing hormone; TRH: thyrotropin releasing hormone; TSH: thyroid-
stimulating hormone.
Symptom Clinical findings Present Absent
Not
reported
Increased BMI Hyperphagia 17 0 4
Polyuria/polydypsia Low serum osmolality 7 12 2
Abnormal glucose homeostasis Increased proinsulin, low insulin, increased
65,64 des split proinsulin
15 5 1
Malabsorptive diarrhea Mild villous atrophy, elevated progastrin and
GLP-1 precursors, normal procalcitonin
21 0 0
Decreased linear growth Growth hormone deficiency; low IGF-1 5 9 7
Hypogonadotropic hypogonadism Low FSH, low LH, low testosterone 7 9 5
Hypothyroidism Low TRH, high TSH, low free T4 13 6 2
Hypocortisolism Normal ACTH, elevated ACTH precursors 12 4 5
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PC1/3 deficient patients died in early childhood (85, 88,
92). Despite the fact that intestinal biopsies did not reveal
clear abnormalities inmost patients,malabsorption of fat,
amino acids and sugars has been confirmed in all the cases
studied so far. Immunohistochemical staining of intestinal
biopsies from PCSK1 null patients showed normal stain-
ing of chromogranin A, but absence of both PC1/3 and
PC2 expression (90). The severity of the malabsorption,
despite the anatomical integrity of the gut and the pre-
served villous architecture, is remarkable and unex-
plained. In this regard, childrenwithmutations in the tran-
scription factor neurogenin 3, required for endocrine cell
fate specification, have a similar syndrome (94), which
illustrates the fact that the function of this scattered en-
teroendocrine cell population has a crucial, but as yet
poorly understood role in the control of absorption by the
mucosal surface of the GI tract. It is important to mention
that both the malabsorptive dysfunction and chronic di-
arrhea tend to slightly diminish with time, concomitantly
with the rapid weight gain of the children.
Hypogonadotropic hypogonadism
Several casesofhypogonadotropichypogonadismhave
been reported in patients lacking PC1/3 activity. The first
reported adult woman with PC1/3 deficiency exhibited
low-serum estradiol, follicle-stimulating hormone (FSH)
and luteinizing hormone (LH), and absence of menstrua-
tion (82, 83). She became pregnant (with quadruplets)
after the administration of gonadotropins to induce ovu-
lation (82). Since then six other different cases of hypo-
gonadism have been reported in infants, five boys with
micropenis and one girl with delayed puberty (87, 88, 90).
No evidence of male hypogonadism was described in six
other infants. The treatment of one male patient with mi-
cropenis with monthly testosterone injections for 3
months resulted in the normalization of his penis size (87,
88, 90).
Hypothyroidism, hypocortisolism, growth hormone (GH)
deficiency and diabetes insipidus
More than half of the PC1/3-deficient patients were
diagnosed to exhibit central hypothyroidism and hypoco-
rtisolism (Table 1), as demonstrated by their lowbloodT4
and cortisol levels without elevations in thyroid-stimulat-
ing hormone (TSH) and ACTH respectively. Hypothy-
roidism and hypocortisolism can contribute to many of
the symptoms observed in PC1/3 null patients including
fatigue, weight gain, constipation and abnormal men-
strual cycles (82, 86, 88).Growth hormone deficiencywas
only diagnosed in a limited number of patients and led to
reduced growth in these patients (88, 92). Interestingly,
however, in a recent meta-analysis, Nead et al identified
the single nucleotide polymorphisms (SNPs) rs6234-
rs6235 to be significantly associated with reduced body
length (95). Diabetes insipidus has been reported in a sub-
set of PC1/3 null patients (85–88).
B. Heterozygous mutations contribute to obesity
Initially, the syndrome was described as recessive, as
childrenof the first patientwerenotobese (83).Lossofone
wild-type allele was not expected to result in a severe phe-
notype. In 2012, Froguel and coworkers identified eight
novel heterozygousmutations in extremely obese patients
(73). These mutations were not present in a control pop-
ulation of 6000 nonobese individuals. The limitation of
this study was that most mutations were unique and not
replicated in neither obese nor in control populations. For
instance the PCSK1-p.N180S mutation identified in an
extremely obese patient was recently identified in a lean
patient (96). Only one mutation, PCSK1-p.Y181H, was
convincingly replicated in the obese cohort, suggesting its
association with obesity. Conversely, despite the location
of thismutation in the catalytic domain, it did not alter the
enzymatic activity using a fluorogenic substrate in in vitro
experiments, indicating that enzyme activity is not the
only determinant for PCSK1 related obesity.
In 2014, Philippe et al reported on a family with dom-
inant Mendelian inherited obesity (96). Sequencing of
genes linked to knownmonogenic obesity, revealed a non-
sense mutation in the second exon of PCSK1. The trun-
cated protein contained the N-terminal propeptide and
was shown to partly inhibit the wild-type enzyme in vitro
(96). This indicates that expression of mutant PC1/3 can
have dominant negative effects on the wild-type protein
function. However, the dominant inheritance did not re-
sult in the full scope of endocrinopathies associated with
PC1/3null patients, confirming residualPC1/3activity.As
described above, the inhibitory function of PC1/3 prodo-
main was already established in vitro (54, 56, 57). The
earlier described PCSK1-p.G209R mutant which was
shown to retain the PCSK1-p.P258T hypomorph in the
ER, could have a similar limited dominant negative effect
(89). Aside from a clear relationwith increased BMI in the
reported patients, it remains unclear whether heterozy-
gosity can lead to other endocrinopathies which are re-
ported for null patients. Some, but certainly not all, car-
riers of PC1/3 null mutations were reported to be obese
(Dr. M. Martin, UCLA, CA - USA; personal
communication).
C. Single nucleotide polymorphisms in PCSK1 increase
the risk of obesity in the population
In a study by Benzinou et al three nonsynonymous
SNPs, rs6232, rs6234-rs6235, in PCSK1 were identified
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tobeassociatedwith extremeobesity in seven independent
European case-control studies (97). The SNPs encode the
PCSK1-p.N221D (rs6232), PCSK1-p.Q665E (rs6234)
and PCSK1-p.S690T (rs6235) amino acid changes, re-
spectively, of which the latter two SNPs are in linkage
disequilibrium. The minor allele frequencies (MAF) in a
global population for rs6232 and rs6234-rs6235 are 2%
and 26% respectively (dbSNP database, average across
ethnicities). However rs6232 is extremely rare in non-
Caucasian ethnicities (5% inCaucasian). In vitro assays
showed that the PCSK1-p.N221D variation causes a sig-
nificant decrease in enzymatic activity (89, 97). The
PCSK1-p.Q665E-p.S690Tvariationwasnot shown tode-
crease enzymatic activity but could have an effect on pro-
tein sorting and stability as it is located in the C-terminal
domain (98). The results by Benzinou et al were subse-
quently only partly confirmed in different case-control
studies from different ethnic origins (99–106). Similarly,
in individual studies for BMI or genome wide association
studies (GWAS) for BMI, either weak associations or no
association were identified (99, 102, 105, 107–112). To
challenge the evidence on the associations ofPCSK1 SNPs
with obesity and BMI, twometa-analyses were conducted
independently (95, 113). Both studies confirmed an asso-
ciation of rs6232 and rs6234-rs6235 with obesity with
odds ratios of 1.15 (1.06–1.24) and 1.07 (1.04–1.10),
respectively. For rs6232, the association was only present
for obesity grade I subgroups, but not for obesity grade II
and III subgroups. For rs6234-rs6235, the associationwas
significant for all subgroups. No association was identi-
fied inAsian cohorts. Both SNPs associatedwith increased
BMI and waist circumference (WC), albeit with only a
small effect size (increase of 0.02–0.03 BMI units or 0.2–
0.4 cm for WC per allele). The effect of the minor alleles
on obesity traits was larger in childhood and adolescent
cohorts compared to adult cohorts. Interestingly, Nead et
al reported that the SNPs rs6234-rs6235 are associated
withadecreasedheight (95).Noassociationwas found for
rs6232, which could be because of the low power of the
analysis to detect a small difference.
Pickett et al identified another less frequent SNP in
PCSK1 to have amoderate effect onPC1/3 function (114).
The nonsynonymous SNP rs1799904 encodes PCSK1-
p.R80Q which is located at the secondary cleavage site in
PC1/3 prodomain. The mutation was shown to reduce
enzyme activity in an in vitro activity assay (38%–48%
decrease). This SNPs is however very rare as currentMAF
is estimated at 0.74% (dbSNP database).
Three additional SNPs located within or in close prox-
imity ofPCSK1 have been associatedwith obesity or BMI.
In intron 6 of PCSK1, rs155971 has been associated with
obesity in a Chinese population (99). In addition,
rs261967 was associated with BMI in East Asians and
rs2570467 was weakly associated with waist circumfer-
ence in a population of African ancestry (115, 116), both
SNPs lie in close proximity of PCSK1. Furthermore, dif-
ferent SNPs in or near PCSK1 have been associated with
growth traits, body weight and fat deposition in different
animal species, such as pigs, bovine, chicken and goats
(117–120). Many of these SNPs were either synonymous
or located in introns or in the 5UTRofPCSK1 gene in the
respective animal genome. Although these SNPs did not
alter protein sequence, it is possible that mutations in in-
trons or 5UTR influence the expression and or splicing of
the gene (117–120). Synonymous SNPs could decrease
mRNA stability or influence protein function as was for
instance shown for themultidrug resistance 1 geneMDR1
(121, 122), yet no evidence exists that this is the case for
PCSK1.
III. PC1/3 substrates which contribute to the PC1/3 null
phenotype
A. PC1/3 activates key players in central energy
homeostasis pathway
The identification of PC1/3 deficiency in monogenic
obesity suggested that substrates of PC1/3 must regulate
feeding behavior and energy homeostasis. As described
above, PC1/3 is expressed in different regions of the brain
which are important for food consumption and metabo-
lism. In the hypothalamus, PC1/3 expression is particu-
larly high in the arcuate nucleus (Arc), more specifically in
leptin-responsive POMC and agouti related peptide
(AGRP)/neuropeptide Y (NPY) neurons. Besides the Arc,
PC1/3 is expressed in several other nuclei of the hypothal-
amus including the magnocellular neurons within the
paraventricular (PVN) and supra-optic nuclei (SON), the
ventromedial hypothalamus (VMH), and the lateral hy-
pothalamus (LH) (Figure 2) (21). PC1/3 cleaves both
orexigenic and anorexigenic substrates which make it dif-
ficult to interpret how the complex interplay of hormonal
cues tips the balance toward increased energy intake and
reduced energy expenditure observed in PC1/3-deficient
patients. In addition to appetite regulation, PC1/3 has
been recently proposed as a new player of the adipose
tissue browning (32). In this section we will discuss dif-
ferent knownandpotential PC1/3 substrateswith a role in
energy homeostasis and feeding behavior.
POMC, AGRP and NPY are expressed in distinct neuronal
populations of the arcuate nucleus
PC1/3 is expressed in various hypothalamic nuclei
known to function as centers for energy homeostasis (Fig-
ure 2). POMC is awell-established PC1/3 substrate which
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Figure 2.
PC1/3 processes many hormones implicated in central and peripheral regulation of feeding behavior and
thermogenesis. This figure includes the important nuclei and endocrine tissues implicated in feeding behavior and thermogenesis. In blue:
different nuclei of the hypothalamus are depicted (ARC: arcuate nucleus; DMH: dorso medial hypothalamus; LH: lateral hypothalamus; PVN:
paraventricular nucleus; SON: supra-optic nucleus; VMH: ventromedial hypothalamus). The nucleus tractus solitarii (NTS), an important peripheral
neuronal nucleus in the brainstem which relays information from the periphery to the hypothalamus, is indicated in orange. Pancreatic islets,
intestinal endocrine cells, and the stomach produce peripheral hormones which can influence feeding behavior by local and central mechanisms.
All peptides listed are either confirmed (gray circles) or potential (white circles) PC1/3 substrates. Note that substrates are confirmed in one tissue
only and tissue-specific redundancy may exist. Orexigenic and anorexigenic peptides are indicated in green and red, respectively. Abbreviations:
AGRP, agouti-related peptide; BDNF, brain-derived neurotrophic factor; CART, cocaine- and amphetamine-regulated transcript; CCK,
cholecystokinin; CRH, corticotropin-releasing hormone; GCG, glucagon; GHRL, ghrelin; GLP-1, glucagon-like peptide 1; HCRT, orexin precursor;
INS, insulin; MCH, melanin-concentrating hormone; NPY, neuropeptide Y; OXT, oxytocin; POMC, pro-opiomelanocortin; PYY, peptide YY; TRH,
thyrotropin-releasing hormone (TRH).
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is expressed indistinct neuronal cell populationsof theArc
(40, 123–126). As described above, PC1/3 and PC2 act in
concert to process POMC to different neuropeptides (as
reviewed in (127, 128)). One such cleavage product is
-MSH, an anorexigenic hormone that exerts its function
by binding to the melanocortin receptors MCR3 and
MCR4. POMC neurons project to over 100 different
brain nuclei, including the PVNand the LHwhere-MSH
can bind the MCR4 leading to a decrease of food intake
and an increase of thermogenesis (129). Deficiency of
-MSH, another POMC-derived peptide, also predis-
poses to obesity in humans, but -MSH is a product of
PC2cleavageonly (130).Conversely,AGRP,which is pro-
duced mainly by PC1/3 from its precursor proAGRP in
AGRP/NPY-expressing neurons, is an orexigenic hor-
mone that antagonizes the -MSH effects by direct com-
petition for the binding to the MCR4 receptors (126).
Therefore, given that both AGRP and -MSH are prod-
ucts of PC1/3 action, it is complex to fully understandhow
PC1/3 deficiency favors increased food intake. Patients
with congenital POMC deficiency and Pomc knockout
mice suffer from hyperphagia and early-onset obesity
(131, 132). Ablation of AGRP/NPY neurons in mouse
neonates or Agrp gene knockout, however, does not alter
feeding behavior indicating that developmental compen-
satory mechanisms exist (133, 134). Removal of AGRP/
NPY-expressing neurons at adult age does, however,
cause severe hypophagia in mice (133, 134). NPY, which
is most likely a PC2 substrate (135–139), is coexpressed
with AGRP in the same neuronal population of the Arc.
NPY exerts orexigenic actions through the depolarization
of POMC neurons, which results in an inhibition on the
action of-MSH.UnlikeAGRP,NPYdoes not bind to the
MCR4 receptor but to NPY1R and NPY5R (140).
CART and BDNF
Cocaine- and amphetamine-regulated transcript
(CART) is aneuropeptideactivatedbyPC1/3 (141),which
is expressed in several nuclei of the hypothalamus. The
receptor for CART has not been identified, troubling the
identification of its function. When infused in the ventri-
cle, CART has an anorexic effect (142). Although it is
coexpressed with POMC in the Arc, some evidence shows
that its anorexic effect is mediated through the nucleus
tractus solitarii (NTS) (143). This nucleus, located in the
dorsal vagal complex (DVC) in the brainstem, is the pri-
mary site for receipt of vagal afferent innervation from the
gut and also expresses POMC (Figure 2).
Brain derived neurotrophic factor (BDNF) is coex-
pressed with PC1/3 and therefore qualifies as a potential
PC1/3 substrate (144). BDNF is primarily expressed in the
VMH and to lesser extent in the PVN and LH (145). Dif-
ferent reports have described that the infusion of BDNF
leads to hypophagia, and that Bdnf/- mice are hy-
perphagic (146). Given that there is no or little expression
of the BDNF receptor in the Arc, it is unlikely that BDNF
directly regulatesPOMCorAGRP/NPYexpression. In the
VMH, BDNF-expressing neurons project to various re-
gions in the brain including theNTS, which also expresses
POMC (145). Thus, it might be conceivable that other
interfacesbetween the leptin-melanocortin signalingpath-
way and BDNF exist. Recent evidence has demonstrated
that the loss of PC7 in mice reduces proBDNF processing
by 36% (147). Both the Pcsk7 and Bdnf knockout mice,
and heterozygous patients carrying BDNF inactivating
mutations exhibit impaired cognitive function. However,
the Pcsk7 knockout mouse model was not reported to be
obese nor hyperphagic. The moderate reduction of
proBDNF processing in Pcsk7 knockout mice and the ab-
sence of an obese phenotype suggests that PC7 only pro-
cesses proBDNF in distinct cell types related to cognitive
impairment. Possibly PC1/3 accounts for processing of
proBDNF in nuclei related to feeding behavior (83,
146–149).
Melanocortin concentrating hormone, Orexin A and B,
and Oxytocin
Both melanin concentrating hormone (MCH) and
orexins (A and B) are thought to influence reward and
motivational cues for feeding. Both peptides colocalize
with PC1/3 in the LH (150). ProMCH is processed by
members of the convertase family toMCHand neuropep-
tide EI (NEI). The latter is a product of PC2 cleavagewhile
the convertase responsible for the first cleavage resulting
in MCH has not been yet identified (151). Intracerebro-
ventricular (icv) injection of MCH leads to hyperphagia
and MCH knockout mice were hypophagic and 28%
lighter thanwild type littermates (152). Administration of
exogenous orexin A to the LH, DMH and PVN led to
hyperphagia, but notwhen injected in other hypothalamic
regions or the brainstem (153). Oxytocin is mainly ex-
pressed in the SON and PVN and is a potential PC1/3
substrate, although the knockout mouse models suggest
complete redundancy with PC2 (154, 155). Besides other
well established functions of oxytocin, as a stimulus for
sex drive and lactation, this neuropeptide also has an an-
orexic effect. Possibly it influences appetite through the
amygdala, VMH, DMH or NTS (156).
B. Peripheral feeding cues are regulated by PC1/3
processing
Different peripheral hormones have been reported to
influence feeding behavior. Several of these hormones are
secreted by the gut in response to food intake and relay to
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the nervous system via the vagal nerve to the DVC (Figure
2). PC1/3 is the enzyme responsible for the activation of
some of these hormones that function as peripheral feed-
ing cues and signal in various metabolic processes.
Ghrelin
Ghrelin has convincingly been shown to be a PC1/3
substrate in mice (157, 158). For its function, the precur-
sor must be octanylated and cleaved to yield the 28 amino
acid ghrelin. The peptide requires both modifications for
binding to the ghrelin receptor. Ghrelin is not only ex-
pressed in the stomach and duodenum but also in certain
hypothalamic areas including Arc, SON and PVN (159,
160). Ghrelin release promotes food intake, gastric mo-
tility, and GH secretion, and has a trophic effect on intes-
tine endothelium. In the Arc it activates AGRP/NPY neu-
rons and thereby promotes feeding behavior. Besides this
direct action as orexigenic hormone, it is hypothesized
that ghrelin is implicated in reward andmotivation (161).
Cholecystokinin
Cholecystokinin (CCK) is a gut hormone secreted by
the small intestinemucosae cells, enteric nerves or neurons
of the central nervous system (CNS). In the intestine, its
secretion is stimulated by certain amino acids and fat con-
tent in the chyme when entering the duodenum. In the
CNS CCK is most likely processed by PC2, but PC1/3
could be the physiological convertase in theGI tract (162–
166). CCK acts primarily through CCK receptors on pri-
mary vagal afferents wiring to the NTS (167). In addition
it aidsdigestionby inhibitinggastric emptying, gastric acid
secretion and by promoting secretion of pancreatic en-
zymes. It also increases the production and secretion of
hepatic bile which is necessary for fat absorption.
Glucagon-like peptides
Proglucagon is processed in the intestinal L cells to
GLP-1,GLP-2 andoxyntomodulin,mainly, if not only, by
PC1/3 (85, 148). The plasma levels of GLP-1 and GLP-2
were found to be decreased in several PC1/3-deficient sub-
jects, although it was not determined for all patients (85,
86, 91). In Pcsk1 knockout mice intestinal proglucagon
processing was absent (148). GLP-1, which is an incretin,
reduces appetite and glucagon secretion, and inhibits gas-
tric emptying. GLP-1 can also be synthesized locally in
neurons that project to the brainstem and hypothalamus
(168).GLP-2hasa trophic effect in the intestine anddelays
gastric emptying. Oxyntomodulin decreases food intake
and increases thermogenesis, albeit it is unclear which re-
ceptor is responsible for these effects. Proglucagon is also
expressed in the pancreatic -cells, where the PC1/3 levels
are very low. Here, proglucagon is predominantly pro-
cessed by PC2 to yield glucagon, which is released into the
bloodstream. Glucagon is important for increasing glyce-
miaby stimulatinghepatic gluconeogenesis. Increased lev-
els of glucagon have been described in some patients (91),
but this increase could be due to unspecific detection of
proglucagon.
Insulin
Insulin is produced by the pancreatic -cells and is the
product of PC1/3 and PC2 mediated cleavage of proinsu-
lin (41, 42, 169–171). In PC1/3-deficient patients the lev-
els of proinsulin and 64,65-des-split proinsulin are abnor-
mally high, whereas in control samples this cleavage
product is almost undetectable (82, 85, 86, 88, 91, 92).
Proinsulin has only 2%–5% of the activity of insulin
which is compensated for by secretion of vast amounts.
However, proinsulin has a 4–6 times longer half-life than
insulin, which is probably the cause of the postprandial
hypoglycemia reported in several patients. It is well-es-
tablished that human proinsulin is first cleaved by PC1/3
after residue 32 and subsequently by PC2 after residue 65
(82, 172, 173). This almost obligate sequential cleavage is
less constrained in rodents, where two nonallelic genes for
proinsulin, proinsulin I and II, exist. Unlike mouse pro-
insulin II, mouse proinsulin I can be processed at both
positions by PC2 (172). The primary function of insulin is
promoting glucose uptake, glycogen synthesis, and inhi-
bition of lipolysis. Insulin processing defects cause diabe-
tes and can in turn contribute to obesity. In addition, it has
been reported that deletionof the insulin receptor from the
brain influences hepatic insulin sensitivity (174, 175). Fur-
ther research showed that both leptin and insulin use sim-
ilar signaling pathways potentially explaining the effects
of insulin on feeding behavior and thermogenesis (176).
C. PC1/3 processing of gut hormones in the GI system
In the GI tract, PC1/3 is highly expressed in diverse
hormone-producing cells of the small intestine. For in-
stance, PC1/3 colocalizes with the vast majority of cells
which express the gut hormones CCK, proglucagon, and
substance P, and in a high percentage of glucose-depen-
dent insulinotropic polypeptide (GIP)-expressing cells
(29, 177, 178). PC1/3 is also colocalizeswith progastrin in
antral G-cells (179). Whereas the processing of progluca-
gon (as discussed above), progastrin and proGIP by PC1/3
in the endocrine intestinal L, G and K cells, respectively,
has been well demonstrated, its participation in the pro-
cessing of proCCKandprosubstance P remains to be dem-
onstrated. In the endocrine intestinal K cells of the upper
intestine the generation of the incretin hormone GIP is
exclusively dependent on the PC1/3 activity (178).Despite
the ability of PC2 to properly produceGIP fromproGIP in
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several endocrine cell lines, the processing of proGIP was
unaltered in intestinal extracts from mice lacking PC2,
suggesting that PC2 is not essential for the production of
GIP (178). Furthermore, PC1/3 is the major convertase
involved in the production of gastrin in antral G-cells
(179, 180), albeit PC2 has been also proposed to partic-
ipate in the cleavage of progastrin, consistent with the
reducedbutnot absent gastrin in thenull patients (85,181,
182).
D. Other substrates associated with PC1/3-related
endocrinopathies
Hypogonadotropic Hypogonadism
For a complete sexual maturation and successful re-
production, a number of neuropeptides, hormones and
sex steroids work in a coordinated fashion across the hy-
pothalamic-pituitary-gonadal (HPG)axis.Among this va-
riety of hormones, the only one that can potentially be
proteolytically activated by PC1/3 is progonadotropin re-
leasing hormone (pro-GnRH). Accordingly, PC1/3 is well
expressed in the hypothalamus, which contains GnRH-
enriched areas, supporting the idea that it could partici-
pate in the activating cleavage of pro-GnRH in GnRH
neurons (183). However, evidence exist that PC2 is also
able to activate proGnRH (183). Aside from a possible
role in the processing of pro-GnRH, PC1/3 could be also
participating in the regulationof theHPGaxis through the
proteolytic activation of KISS1 or tachykinin B in the hy-
pothalamus. It has recently been described that PCs may
be required for theprocessingKISS1 tokisspeptinpeptides
(88, 90, 184).Whether PC1/3 is responsible for theKISS1,
pro-GnRH or tachykinin B processing in the respective
neurons, remains to be established.
Hypothyroidism
In the early nineties prothyrotropin releasing hormone
(proTRH)wasput forwardasaPC1/3 substrateby invitro
studies (185). This was recently confirmed by peptidomic
analysis of mouse brain and by direct comparison of pro-
TRH processing in PC1/3 and PC2 knockout mice (81,
186, 187). Although PC1/3 was found to be the main
physiological proTRH converting enzyme, PC2 cleaves it
as well, albeit it to a lesser extent (187). ProTRH is pro-
duced in the PVN and its expression and secretion is stim-
ulatedbyneuropeptides related to the leptin-melanocortin
pathway. For instance, -MSH stimulates and AGRP in-
hibits proTRH expression. TRH is released into the blood
via the portal vessels of the median eminence. In the pi-
tuitary, TRH induces the secretion of TSH, which in turn
stimulates the thyroid gland. The active hormones T4/T3
released by the thyroid gland are important to drive the
metabolic rate. The implication of PC1/3 deficiency on the
secretionofTRHis twofold: firstly, reducedproductionof
-MSH leads to a decrease of TRHexpressionwhichmay,
at least in part, be compensated by reduced amounts of
AGRP; and secondly proTRH has been identified as a
PC1/3 substrate (185, 187).
Hypocortisolism
The processing of POMC by PC1/3 and PC2 is well
established and it is known that only PC1/3 is expressed in
the ACTH-producing corticotroph cells of the anterior
pituitary. Plasma ACTH stimulates adrenal expression of
cortisol. Strikingly, in Pcsk1 knockout mice, no ACTH
was produced, yet corticosterone levels were normal
(148). How mice can remain eucorticosteronemic in the
absence of ACTH is unknown. Since the initial observa-
tion has not been confirmed in other studies, it is possible
that either the physiologicalACTHconcentrationwas un-
derestimated or the corticosterone concentration was
overestimated in Pcsk1 knockout mice. Similarly in pa-
tients, reduced plasma ACTH, increased ACTH precur-
sors, and near normal cortisol levels were observed (85).
Potentially, ACTH precursors might retain some affinity
for theACTHreceptor explaining thenearnormal cortisol
levels in patients. Alternatively, another endoprotease or
proprotein convertase could process POMC to ACTH in
the absence of PC1/3. In addition, PC1/3 could be the
putative convertase responsible for the activation of pro-
corticotropin releasing hormone (CRH) (188) since the
production of CRH is not altered in the hypothalamus of
Pcsk2 knockout mice (136, 189). However, no direct ev-
idence exist that CRH is a substrate for PC1/3.
Growth hormone deficiency
Several studies have demonstrated that progrowth hor-
mone releasing hormone (proGHRH) processing to
GHRH is mediated by furin and PC1/3 (190, 191), which
can explain the growth retardation observed in several
human patients (Table 1). Interestingly, Pcsk1 null mice
display severe dwarfismdue to low levels ofGHRH (148).
Given that not all patients exhibit GH deficiency, most
likely another convertase provides limited redundancy in
human but not mice. Mouse proGHRH is cleaved at two
positions (RMQR30 and RLSR73) to yield GHRH31–73
(191). For both sites the P2 positions are not conserved in
humans (RMRR31 and RLGR77). In particular, the
RMRR31 site is an improved cleavage site, making it a
more likely substrate for additional convertases.
Diabetes insipidus
Vasopressin colocalizes with PC1/3 in the magnocellu-
lar neurons of the SON (21). Therefore, aberrant prova-
sopressin processing is a likely cause for diabetes insipidus
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in PC1/3 null patients. In fact, PC1/3 can process prova-
sopressin at the neurophysin/glycopeptide boundary and
the vasopressin/neurophysin boundary in vitro (154).
However, brain neuropeptidomic studies in Pcsk1 and
Pcsk2 null mice showed no alterations in provasopressin
expression (81, 192, 193). PCSK1 null patients with dia-
betes insipidus were successfully treated with desmopres-
sin, a vasopressin analog, substantiating the importanceof
PC1/3 in the processing of provasopressin (85–88, 90, 92,
93, 194). Sequence comparison indicates that the vaso-
pressin/neurophysin cleavage site is conserved between
mice and men, but not the neurophysin/glycopeptide
cleavage site (RRAR125) in human vs RLTR129 in mice).
IV. PC1/3 deficiency: a clinical perspective
A. Clinical presentation
The clinical manifestations of PCSK1 deficiency show
considerable interindividual variation. This presumably
reflects the impact of genetic background on the ability of
other convertases to compensate for particular defective
proprotein conversion events and/or variability in the ex-
tent to which elevated levels of incompletely processed
precursors can continue to have bioactivity at their cog-
nate receptors.
PCSK1 deficiency does not appear to impair prenatal
growth and development and all children described thus
far have been born at full term after an uneventful preg-
nancy. It is now clear that by far themost common clinical
presentation of PCSKI deficiency is severe malabsorptive
diarrhea becoming clinically evident within the first three
months of life. This can be so severe as to lead to a met-
abolic acidosis. The failure of this diarrhea to resolve, usu-
ally leads to early specialist referral and investigations and,
not infrequently, the need for nutrition to be delivered
parenterally (83, 85, 86, 88, 90, 92, 93). After the age of
two years, the severity of the malabsorption appears to
spontaneously improve and many children can discon-
tinue parenteral feeding. To date, there is no therapy that
can reliably accelerate that spontaneous improvement.
Despite the improvement, patients appear prone to per-
sistent diarrhea and bloating which can be life-long. The
index case also suffered fromepisodes of constipation, but
this has never been reported since (82).
Guidelines fordifferential diagnosis of chronic infantile
diarrhea have been developed (as reviewed in (195, 196).
Patients presenting with idiopathic pediatric chronic di-
arrheawith generalizedmalabsorptionbut normal or near
normal histologyof the intestines should be considered for
PCSK1 deficiency. Using these criteria, Martin et al iden-
tified that approximately 25%–30% of the selected pa-
tients were homozygous or compound heterozygous for
deleterious PCSK1 mutations (88).
Over the subsequent childhood years the clinical man-
ifestations which most frequently emerge, are persistent
diarrhea, obesity, diabetes insipidus (86), and reactive hy-
poglycemia, albeit with variable severity. The obesity is
usually associated with hyperphagia. The reactive hypo-
glycemia can be severe and lead to neuroglycopenic epi-
sodes several hours after a meal. Despite the fact that pro-
insulin processing is markedly abnormal, sometimes
resulting in little ornomature insulin in the circulation, the
biological activity of the highly elevated levels of proin-
sulin means that diabetes mellitus is not a frequent early
clinical issue in patients. However, as patients age, diabe-
tes can emerge as a clinical problem, presumably at least
partly attributable to “beta cell exhaustion”, and insulin
treatment may be required (observation made for the in-
dex patient by Dr. S. O’Rahilly, University of Cambridge,
UK).
Problems of impaired linear growth and short stature
are not a hallmark feature, yet reducedGH levels has been
observed in at least five patients (Table 1). The finding that
the polymorphism rs6234-rs6235 is mildly, yet signifi-
cantly ( –0.02240.0033,P5.4	10–11,N251
342), associated with decreased length seems to indicate
mild impairmentof theGHRH-GHaxis (discussed further
below) (95). Reduced growth could partially account for
increased BMI of some of the heterozygous and homozy-
gous patients.
Hypogonadotropic hypogonadism with failure of pu-
bertal development is a striking feature in many patients
(indeed the index case was amenorrheic until treated with
gonadotropins for infertility in her early twenties (82)).
Almost all patients show, when appropriately tested,
biochemical evidence of impairment of the hypothalamic-
pituitary-adrenal and hypothalamic-pituitary-thyroid
axes although severe, clinically apparent deficiencies or
either cortisol or thyroxine are rarely seen. Anecdotally,
some patients report highly abnormal sleep/wake cycles.
B. Diagnosis
PC1/3 deficiency is a very rare genetic disorder; thus far
only 21 patients have been reported (82, 83, 85–88, 90–
93). It is very likely, however, that more patients miss
diagnosis or die soon after birth. Therefore, guidelines are
needed for rapid differential diagnosis and proper treat-
ment. The normal conversion of proinsulin to insulin is
absolutely dependent on PC1/3 function in human pan-
creatic islets. The measurement of the circulating ratio of
proinsulin to insulin is therefore a sensitive biochemical
screen for the presence of PCSK1 deficiency. Targeted se-
quencing of PCSK1 exons and intron exon boundaries is
doi: 10.1210/er.2015-1117 press.endocrine.org/journal/edrv 13
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 18 May 2016. at 00:24 For personal use only. No other uses without permission. . All rights reserved.
undertaken in several laboratories with a particular inter-
est in this condition. The rapidly decreasing cost of whole
exome andwhole genome sequencingwill probably result
in this soon becoming the main route for analysis (90, 92,
197).
C. Management
As it is a germline genetic disorder expressed through-
outmany endocrine cell types in the body there is currently
no specific targeted therapy for PCSK1 deficiency. Man-
agement in early life is largely focused on supplying ade-
quate nutrition in the face of severe diarrhea and complete
parenteral nutrition is often required. It is of interest that
a GLP-2 analog, teduglutide is now licensed for the treat-
ment of the diarrhea of the short bowel syndrome (198).
As proglucagon processing is severely disrupted inPCSK1
deficiency the examination of the effects of this agent in
affected patients with severe diarrhea would be of consid-
erable interest.
Early evaluation of the thyroid, adrenal axes is recom-
mendedwith appropriate correction of any deficiencies. A
high index of suspicion for symptoms suggestive of dia-
betes insipidus or reactive hypoglycemia should be main-
tained and appropriate investigations undertaken if rele-
vant symptoms present themselves. Hypogonadotropic
hypogonadism is common and the reproductive axis
should be evaluated around the time of normal puberty
and, when necessary, appropriate sex steroids should be
used to induce and maintain pubertal development. Af-
fected patients are likely to require assisted conception if
this issue arises.
Obesity can be a challenging problem for patients. No
clinical trials of antiobesity strategies or weight loss pro-
motingdrugshavebeen specifically undertaken inpatients
withPCSK1deficiency and therefore experience is entirely
anecdotal. It is likely that the lack of -MSH tone in the
hypothalamus is a contributor to the obesity and therefore
patients with PCSK1 deficiencymight benefit from agents
that act centrally to reduce appetite. Several such agents
(Orlistat, Lorcaserin, Phentermine/Topiramate, Naltrex-
one/Bupropion, and Liraglutide (199, 200)) are now li-
censed for the treatment of obesity, thoughall have limited
therapeutic efficacy and a range of side effects. To our
knowledge, bariatric surgery has been used as a treatment
for obesity in only one patient with PCSK1 deficiency. At
50 years of age the index case reported in (82, 83) un-
derwent Roux en Y gastric bypass surgery. This was re-
markably effective with a loss of more than 25% of body
weight and a reversal of diabetes which had previously
required over 200 U of insulin daily. Normoglycemia
without treatment has persisted for more than 10 years.
V. The PCSK1 mouse models conundrum
A. Pcsk1 knockout mice: an unexpected phenotype
Two Pcsk1 knockout mouse models have been devel-
oped so far. The first and most used KO model was de-
veloped by the Steiner group and reported in 2002 (148).
The gene knockout was established by replacing of a 900
bp fragment of exon 1 with the Neomycin resistance gene
at this location. The homozygous knockout mice suffered
from prenatal lethality and difficulty to thrive as only
20% of the mice survived beyond the first week. The
Pcsk1 knockout mice were growth retarded (40% reduc-
tion in bodyweight) due to a lackof proGHRHprocessing
leading to secondary GH deficiency. Heterozygous ani-
mals were not growth retarded, but became mildly obese
with age.
Proinsulin processing was severely impaired and led to
glucose intolerance in homozygous mice, but not
heterozygousmice. Immunoelectronmicroscopy revealed
increased proinsulin/insulin ratio resulting in secretory
granules with less electron-dense cores and a smaller halo
between the core and the limiting membrane (172). Fur-
thermore, large moist stools were noticed in older Psck1-/-
mice (148), suggesting that, like most PC1/3 null patients,
they suffer from GI disturbances. As described above,
Pcsk1 null animals also exhibited lower circulatingGLP-1
andGLP-2, albeit the association of the deficiency of these
hormones with the malabsorption problems remains elu-
sive. The lack of PC1/3 activity not only causes malab-
sorption of fatty acids in mammals, but also in inverte-
brates such as C. elegans (201). An interesting phenotype
in mice, but not still reported in humans, is that Pcsk1
deficiency causes innate immune defects and uncontrolled
cytokine secretion by macrophages (202). The Pcsk1
knockout mice had an average spleen size which was al-
most double the size of control mice. Moreover the mice
were more sensitive to LPS stimulation, suggesting a role
of PC1/3 in innate immunity.
The second Pcsk1 knockout model was developed by
the Seidah group (203). This mouse model was created by
homologous recombination with a disruption vector
which results in insertion of the Neo gene and excision of
exon 3 to 9, but suffered from preimplantation lethality.
Further investigation showed that a fusion protein was
expressed which contained an N-terminal 85 amino acid
sequence from PC1/3 fused to 46 amino acids from the
Neo gene. This fusion protein, containing most of the in-
hibitory propeptide of PC1/3 was shown to be able to
inhibit other PCs in vitro as well. The broad inhibition of
this fusion protein is likely to cause the more severe phe-
notype observed in themousemodel, compared to the first
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mousemodel and prevents its use to identify physiological
substrates.
B. The Pcsk1-N222D hypomorph mouse as a model of
obesity
The hypomorphic N222D mutation in the Pcsk1 gene
was identified in an obese mouse line (204). This mouse
model was generated using a forward genetic screen with
N-ethyl-N-nitrosourea asmutagen.Themousemodelwas
reported to have augmented body weight and a dominant
increase in body fat content when given a high fat diet
(204). Accordingly, the PC1/3-N222D mice are glucose
intolerant (but insulin sensitive), hyperphagic, have in-
creased fat gain efficiency, and have a normal resting en-
ergy expenditure (204), like observed in some patients
(86). The Pcsk1N222D/N222D mice are also less fertile as a
consequence of reduced levels of plasma gonadotropins
and testosterone (204), suggesting an alteration in the hy-
pothalamic-pituitary-gonadal axis of these animals. In
vitro experiments using a fluorogenic substrate demon-
strated that whereas the humanPCSK1-N222D construct
showedonly a reduction of roughly 50%(204), themouse
Pcsk1-N222D construct was virtually inactive (205). Ac-
cordingly, this mutation resulted in a decrease in the pro-
cessing of substrates such as proinsulin (204, 206) and
hypothalamic and pituitary POMC (204). In contrast to
thePcsk1knockoutmice, thePC1/3-N222Danimalswere
able to properly process other physiological substrates in-
cluding in the GHRH-GH-IGF1 axis, resulting in normal
size. Additionally, the N222D mutation affected the au-
tocatalytic C-terminal processing of PC1/3 as demon-
strated by the absence of the 66-kDa form in different
tissues (205). The loss of function of PC1/3-N222D has
been associated to its partial retention in the ER, which
results in its rapid degradation by the proteasome via ER
associated degradation (ERAD) (206). Since autocatalytic
propeptide cleavage is not severely
affected in TC-3 cells, this suggests
that the N222D mutation hampers
further folding of the protein after
cleavage at the primary site. This
might results in an unstable protein,
prone to unfolding and largely un-
able to pass the ER quality control
(QC).
VI. Functional consequences of
human PCSK1 variants: hints from
mice
A. PC1/3 variants and obesity; the
calcium binding site as the culprit?
The identification of extremely
obese patients heterozygous for
PCSK1 mutations and the associa-
tion of PCSK1 SNPs with obesity
challenged the recessive nature of the
PCSK1-related syndrome (73, 96,
97, 113). Some of these mutations
and variations do not alter PC1/3 ac-
tivity in vitro and have only mild de-
fects on autocatalytic processing in
theER. Interestingly, five of the iden-
tified mutations (M125I, T175M,
N180S, Y181H, G226R), the muta-
tion identified in the obese mouse
model (N222D), and the SNP
rs6232 (N221D) affect residues that
cluster around the calcium-1 (Ca-1)
binding site (Figure 3), which has
Figure 3.
Proposed model for the dominant negative effect of certain ER-retained PC1/3
mutants on wild-type PC1/3. Some PCSK1 mutations are known to cause misfolding and
ER retention of PC1/3. In addition to the inactivation of this ER-mutants itself, recent evidence
suggest that these mutations (indicated with red star) negatively impact the levels of wild-type
PC1/3 through the formation of heteroduplexes that are targeted for proteasomal degradation
via ERAD. Other mutations (indicated with black star) that are properly folded, however, would
also dimerize with wild-type PC1/3, but in this case the heteroduplex is not degraded and both
proteins are able to exit the ER. The extent of UPR and ERAD, elicited by the expression of a
mutant PC1/3 protein, most likely correlates with the metabolic demand of the cell.
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been shown to be important for structural stability in bac-
terial subtilisin (73, 207). Creemers et al proposed that
mutations in close proximity of this calcium-binding site
could alter enzyme stability which could lead to protein
misfolding and thereby decreasing the amount of active
enzyme (73). Recent evidence from our group and the
Lindberg group confirmed that some PCSK1 mutations
lead to protein instability (89, 205). In particular, our re-
sults indicate that several of the identified heterozygous
mutations caused a delayed exit of the mutant protein
from the cell (205).However, this effect was not restricted
to the mutations that are close to the Ca-1 binding site.
B. Endoplasmic reticulum-retained PC1/3 mutants;
dominant negative effect and ER-associated degradation
Many proteins need to oligomerize as a prerequisite for
ER exit (208). Both endogenous and recombinant PC1/3
have been shown to be present in multimeric forms in
CHO and AtT20 cells, and bovine chromaffin granules
(75). PC1/3 is present as monomers, dimers, and oligom-
ers/aggregates, the latter having no activity. Upon dilu-
tion, the oligomers dissociate and activity increases (75).
Thedimers andoligomers are constitutedof87kDaPC1/3
and incubation with substrate stabilizes PC1/3 activity.
Interestingly,Blancoet al recentlydemonstrated that some
ER-retained PC1/3 mutants inhibited PC1/3-WT secre-
tionandactivity (89).Theproposedmechanism to explain
this effect was that ER-retained mutants can oligomerize
with PC1/3-WT in the ER lumen, and the resulting accu-
mulatedheterocomplex canbe targeted todegradation via
ERAD (Figure 3). A similar dominant-negative effect has
been already found for other mutant proteins, such as
mutations in proinsulin found in the Akita mice (173,
209).
Asmentioned above,mouse PC1/3-N222Dwas shown
to be partially retained in the ER, ubiquitinated and de-
graded by the proteasome, which is evidence for ER as-
sociated degradation (206). Taking into account that this
degradation contributes to loss of function of PC1/3, we
can speculate that it could be an important factor for the
etiology of the multiple endocrinopathies associated with
PC1/3 deficiency. In fact, it might explain why PCSK1
variants which appear to partially retain enzyme activity,
are associated with obesity. Generally, PC1/3 activity is
depicted relative to the amount of PC1/3 protein secreted
in the medium. Therefore, the functional defects of mu-
tations in PC1/3 which cause the protein to be partially
secreted and partially retained in the ER might be under-
estimated by a conventional activity assay if the correctly
folded mutant protein performs well in an in vitro assay
against a synthetic substrate.
C. Loss-of-function mutants and the unfolded protein
response
The hypothesis that PCSK1 mutations cause PC1/3
misfolding and ER stress, is a recently emerging concept.
The heterozygous mutations previously identified in ex-
tremely obese patients showed an increased intracellular
retention compared to PC1/3-WT (205). In agreement
with these results, Blanco et al demonstrated that the hu-
man ER-retained PCSK1-p.G209R and PCSK1-p.G593R
variants caused low grade ER stress, identified by in-
creased expression of the ER-resident chaperone BiP and
the ER-stress marker X-box binding protein 1 (XBP-1)
(89). This is in line with our recent results where we ob-
served an increased coimmunoprecipitation of BiP with
some human PCSK1mutants partially retained in the ER
(205). Expression analysis in islets of Langerhans of
Pcsk1N222D/N222D mice showed an enrichment of genes
associated with the proteasome and the unfolded protein
response (more specifically the XBP1-pathway) (205).
Taken together, these studies suggest that certain human
PC1/3variants causemildERstress.The severity of theER
stress may vary per tissue and is likely to be highest in cells
under highmetabolic demand, such as-cells after a high-
fat meal. It is known that ER stress can cause hypotha-
lamic leptin resistance and -cell dysfunction by various
mechanisms (210, 211). Whether PC1/3 mutations asso-
ciated to ER stress are sufficient to cause either leptin re-
sistance or a diabetic phenotype remains to be proven.
VII. Conclusions and future directions
In the last two decades research on PCSK1 variations
and mutations in patients and mouse models has made
important contributions to our current understanding of
mono- and polygenic PCSK1-related endocrinopathies. It
is now clear that PC1/3 deficiency causes a severe endo-
crine disease marked by failure to thrive, severe malab-
sorptive diarrhea, early onset obesity and other endocri-
nopathies to a varyingdegree. Improvedknowledgeon the
syndrome will facilitate early diagnosis which will be nec-
essary to promote survival and wellbeing of the patients.
Advanced genetic diagnostics, such as exome sequencing,
will have a future role in early diagnosing this severe in-
heritable disease (197). Current treatments are focused on
hormone replacement therapies. However, the severe GI
phenotype has not been fully addressed despite the fact
that this phenotype is most likely the largest contributing
factor to the failure to thrive observed in PC1/3-deficient
neonates. GLP-2 analogs, such as teduglutide, which have
been FDA approved for short bowel syndrome, are a
promising candidate drugs to improve the GI phenotype
(198).
Besides PC1/3 deficiency, heterozygous mutations and
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SNPs have also been reported to contribute to increased
obesity parameters (73, 95, 96, 113). The identified non-
synonymous SNPs rs6232 and rs6234-rs6235 could con-
tribute to obesity by reducing PC1/3 function and/or
mildly impairing PC1/3 trafficking in the cell. Other non-
coding SNPs in or nearby PCSK1 have been associated
with obesity parameters and proinsulin disorders (99,
115, 116). It is unclear whether these SNPs alter PCSK1
expression, RNA stability or PC1/3 function. The effects
of both PCSK1 SNPs and mutations on PC1/3 function
and expression still require more research. In addition to
activitymeasurements, all aspectsofPC1/3biology should
be investigated: propeptide removal, ER exit, C-terminal
processing and PC1/3 oligomerization. Measuring cleav-
age of endogenous substrates in cellulo, or preferably in
vivo, should become the new standard of characterizing
PC1/3 enzymatic function in addition to the in vitro use of
synthetic substrates. Therefore, PCSK1 knockout cell
lines are needed, which nowadays can be easily created
using CRISPR-Cas9 technology (212). Furthermore, this
would allow the characterization of PC1/3 variants and
mutants in at physiological levels. To disseminate con-
verging and diverging substrate specificities of PC1/3 and
PC2 the generation of an in silico tool for substrate cleav-
age prediction, like ProP 1.0 for furin (213) or Neuropred
(214), would be useful.
The effect of synonymous SNPs and noncoding SNPs
are more challenging to investigate. RNA stability and
RNA splicing can be investigated for synonymous SNPs.
For assessing the effect of noncoding SNPs in PCSK1 or
near the PCSK1 gene chromatin conformation capture
techniques can be employed (215). This technique allows
the study of chromatin looping and genome architecture.
This can be useful to identify whether SNPs identified by
GWAS are located in cis or in trans regulatory regions.
Alternatively, cellular or animal models can be con-
structed using CRISPR-Cas9 technology (212) to intro-
duce the specific variation, given that the region is con-
servedbetween species. To improve the in silicoprediction
of the effect of PCSK1mutations on enzyme function and
biology, a crystal structure is needed. This would allow
accurate prediction of the effect of amino acid substitu-
tions and protein stability using algorithms to predict pro-
tein folding and aggregation properties (216–218). This
could be of interest in the context of heterodimerization of
PC1/3-WT with mutant proteins.
In conclusion, research on PCSK1mutations and vari-
ations focused on better functional characterization in a
physiologically relevant context is dearly needed. This
would be facilitated by improved knowledge on substrate
specificity, three-dimensional structure, and cellular biol-
ogy. Patients can benefit from this gained knowledge as it
allows for the design of specific drugs aimed at restoring
PC1/3 function or at replacing hormone deficiencies. In
the short term, it is imperative to establish procedures to
diagnose PCSK1 deficiency more rapidly. This will allow
to reduce PC1/3 deficiency related mortality and improve
patient well-being.
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